Analytical Data
-
基因名
ANLN
- Application
-
别名
Scra; Scraps; Actin-Binding Protein Anillin
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NQW6
-
表达区间
Cys712~Pro1124
-
分子量
50&35kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ANLN (anillin) is a crucial actin-binding protein that plays a significant role in the regulation of the cytoskeleton during cell division and maintaining cellular architecture. Research on ANLN has garnered interest due to its involvement in various cellular processes, including cytokinesis, cell adhesion, and migration. Abnormal expression or function of ANLN has been implicated in several pathological conditions, notably cancer, making it a potential biomarker and therapeutic target. The study of ANLN recombinant proteins allows for a deeper understanding of its structural and functional properties, enabling researchers to dissect the molecular mechanisms underlying its role in cell division and disease progression. Through recombinant DNA technology, scientists can produce ANLN in a controlled environment, facilitating the exploration of its interactions with other proteins and its effects on cellular dynamics. This research not only contributes to the fundamental understanding of cytoskeletal dynamics but also holds promise for the development of innovative strategies in cancer treatment and regenerative medicine, as modulation of ANLN activity could provide new avenues for therapeutic intervention.
